WORK Medical Technology Group LTD Financials
WORK Medical Technology Group LTD (WOK) reported $9.8M in revenue for fiscal year 2025, down 14.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
WORK’s cash recovery is being supplied by working-capital release and lower capital spending, not yet by profitable operations
FY2025 combined operating cash flow of$6.2M with a net loss of-$1.1M , so reported earnings materially understate cash generation for the period. Falling receivables and inventory helped support that gap, indicating that cash conversion benefited from balance-sheet movements rather than a profitable operating engine.
Revenue fell from
Total liabilities declined from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of WORK Medical Technology Group LTD's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for WORK Medical Technology Group LTD, and counted as zero in the overall score.
WORK Medical Technology Group LTD's revenue declined 14.4% year-over-year, from $11.5M to $9.8M. This contraction results in a growth score of 7/100.
WORK Medical Technology Group LTD has a moderate D/E ratio of 0.65. This balance of debt and equity financing earns a leverage score of 54/100.
WORK Medical Technology Group LTD's current ratio of 1.71 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.
WORK Medical Technology Group LTD's free cash flow margin of 49.9% results in a low score of 24/100. Capital expenditures of $1.3M absorb a large share of operating cash flow.
Not available for WORK Medical Technology Group LTD, and counted as zero in the overall score.
WORK Medical Technology Group LTD passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
WORK Medical Technology Group LTD reported a net loss of $1.1M while generating $6.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
WORK Medical Technology Group LTD generated $9.8M in revenue in fiscal year 2025. This represents a decrease of 14.4% from the prior year.
WORK Medical Technology Group LTD reported -$1.1M in net income in fiscal year 2025. This represents an increase of 69.3% from the prior year.
WORK Medical Technology Group LTD earned -$0.04 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
WORK Medical Technology Group LTD generated $4.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 142.9% from the prior year.
WORK Medical Technology Group LTD held $4.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
WORK Medical Technology Group LTD's gross margin was 23.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.1 percentage points from the prior year.
WORK Medical Technology Group LTD's net profit margin was -10.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 19.5 percentage points from the prior year.
WORK Medical Technology Group LTD's ROE was -5.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
WORK Medical Technology Group LTD invested $435K in research and development in fiscal year 2025. This represents an increase of 43.9% from the prior year.
WORK Medical Technology Group LTD invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 85.6% from the prior year.
Not reported for fiscal year 2025.
WOK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
WOK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q4'23 |
|---|---|---|---|---|
| Total Assets | $33.2M-4.5% | $34.7M-4.2% | $36.3M+21.0% | $30.0M |
| Current Assets | $20.5M-5.2% | $21.6M+3.6% | $20.8M-6.0% | $22.2M |
| Cash & Equivalents | $4.1M+104.9% | $2.0M-69.6% | $6.6M+310.9% | $1.6M |
| Inventory | $2.5M-17.5% | $3.0M-6.5% | $3.2M-31.1% | $4.6M |
| Accounts Receivable | $616K-29.8% | $877K-46.8% | $1.6M-50.5% | $3.3M |
| Total Liabilities | $12.0M-36.9% | $19.0M-5.9% | $20.2M+6.4% | $19.0M |
| Current Liabilities | $12.0M-36.9% | $19.0M-6.0% | $20.2M+6.6% | $18.9M |
| Total Equity | $18.3M+41.6% | $12.9M-1.8% | $13.2M+33.5% | $9.9M |
| Retained Earnings | $5.0M-18.6% | $6.1M+0.2% | $6.1M-36.6% | $9.6M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
WOK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q4'23 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
WOK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q4'23 |
|---|---|---|---|---|
| Current Ratio | 1.71+0.6x | 1.14+0.1x | 1.03-0.1x | 1.17 |
| Debt-to-Equity | 0.65-0.8x | 1.47-0.1x | 1.53-0.4x | 1.92 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.
Similar Companies
Where WORK Medical Technology Group LTD Ranks
Frequently Asked Questions
What is WORK Medical Technology Group LTD's annual revenue?
WORK Medical Technology Group LTD (WOK) reported $9.8M in total revenue for fiscal year 2025. This represents a -14.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is WORK Medical Technology Group LTD's revenue growing?
WORK Medical Technology Group LTD (WOK) revenue declined by 14.4% year-over-year, from $11.5M to $9.8M in fiscal year 2025.
Is WORK Medical Technology Group LTD profitable?
No, WORK Medical Technology Group LTD (WOK) reported a net income of -$1.1M in fiscal year 2025, with a net profit margin of -10.9%.
What is WORK Medical Technology Group LTD's gross margin?
WORK Medical Technology Group LTD (WOK) had a gross margin of 23.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is WORK Medical Technology Group LTD's net profit margin?
WORK Medical Technology Group LTD (WOK) had a net profit margin of -10.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is WORK Medical Technology Group LTD's return on equity (ROE)?
WORK Medical Technology Group LTD (WOK) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is WORK Medical Technology Group LTD's free cash flow?
WORK Medical Technology Group LTD (WOK) generated $4.9M in free cash flow during fiscal year 2025. This represents a 142.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is WORK Medical Technology Group LTD's operating cash flow?
WORK Medical Technology Group LTD (WOK) generated $6.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are WORK Medical Technology Group LTD's total assets?
WORK Medical Technology Group LTD (WOK) had $33.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are WORK Medical Technology Group LTD's capital expenditures?
WORK Medical Technology Group LTD (WOK) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does WORK Medical Technology Group LTD spend on research and development?
WORK Medical Technology Group LTD (WOK) invested $435K in research and development during fiscal year 2025.
What is WORK Medical Technology Group LTD's current ratio?
WORK Medical Technology Group LTD (WOK) had a current ratio of 1.71 as of fiscal year 2025, which is generally considered healthy.
What is WORK Medical Technology Group LTD's debt-to-equity ratio?
WORK Medical Technology Group LTD (WOK) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is WORK Medical Technology Group LTD's return on assets (ROA)?
WORK Medical Technology Group LTD (WOK) had a return on assets of -3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is WORK Medical Technology Group LTD's Piotroski F-Score?
WORK Medical Technology Group LTD (WOK) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are WORK Medical Technology Group LTD's earnings high quality?
WORK Medical Technology Group LTD (WOK) reported a net loss of $1.1M while generating $6.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is WORK Medical Technology Group LTD?
WORK Medical Technology Group LTD (WOK) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.